{
    "nct_id": "NCT06681220",
    "official_title": "Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC",
    "inclusion_criteria": "* Age 18 years or older at the time of consent.\n* Histological or cytological diagnosis of extensive-stage small cell lung cancer.\n* Patients must have received one prior line of systemic therapy.\n\n  * Patients must have received first-line therapy with Carboplatin and Etoposide.\n\n    * If patient is re-treated with Carboplatin and Etoposide at least 6 months or more after first regimen, this will still be considered one line of\n    * treatment and they will qualify for this trial.\n  * Patients could have received immunotherapy in combination with the chemotherapy regimen.\n  * Patients who have received Tarlatamab as second line treatment are allowed.\n* ECOG Performance status 0-2.\n* Measurable disease as per RECIST v1.1 (NOTE: Previously irradiated lesions are eligible as a target lesion only if there is documented progression of the lesion after irradiation).\n* Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements:\n\n  * ANC 1.5\n  * Platelets 100 × 109/L\n  * Hemoglobin 9 g/dL or 5.6 mmol/L\n  * Aspartate transaminase and alanine transaminase 2.5 × upper limit of normal (ULN), <5× in patients with known liver metastases\n  * Serum total bilirubin 1.5 × ULN, 1.5-3.0 × ULN may be included appropriate starting dose adjustment to 200 mg daily.\n  * Creatinine <1.5 × ULN or estimated glomerular filtration rate (GFR) 50 ml/min by Cockcroft-Gault. Depending on scenario, GFR 30-49 can be --permissible.\n* Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test within 72 hours of cycle 1 Day 1.\n* Male and female subjects of child-bearing potential must agree to use a double-barrier method of birth control from the screening visit through 180 days after the last dose of study drug.\n* Male subjects of child-bearing potential must agree to use a double-barrier method of birth control including use a male condom (and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak) and must agree to refrain from donating sperm from screening visit through at least 90 days after the last dose of study drug.\n* Previously treated or asymptomatic brain metastases are allowed.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Unstable or clinically significant concurrent medical condition, psychiatric illness or social situation that would, in the opinion of the investigator, jeopardize the safety of a subject and/or their compliance with the protocol.\n* Clinically significant acute infection requiring systemic antibacterial, antifungal, or antiviral therapy. (Suppressive therapy for chronic infections allowed, for example: Subjects with HIV/AIDS with adequate antiviral therapy to control viral load would be allowed. Subjects with viral hepatitis with controlled viral load would be allowed while on suppressive antiviral therapy.)\n* Prior exposure to lurbinectedin, TMZ or niraparib.\n* Pregnant or breastfeeding.\n* Subject with known hypersensitivity to niraparib components or excipients including tartrazine 9yellow #5) or any other study products are excluded.\n* Subject with known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) are excluded.\n* Participants have systolic BP >140 mmHg or diastolic BP >90 mmHg that has not been adequately treated or controlled.\n* Any patient with prior history of Posterior Reversible Encephalopathy Syndrome (PRES).",
    "miscellaneous_criteria": ""
}